Hosted on MSN1mon
Acrux scores fourth FDA approval, Nitroglycerin Ointment moving into commercialisationAcrux Ltd (ASX:ACR) has been approved to begin U.S. commercialisation activities for its Nitroglycerin Ointment 0.4% targeting pain related to chronic anal fissures, with this marking the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback